One scan to catch two silent threats: MRI may spot bone and muscle loss in kidney patients

NCT ID NCT07645794

Not yet recruiting Diagnosis Sponsor: Capital Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study explores whether a single MRI fat-fraction (MRI-FF) scan can accurately diagnose osteoporosis and sarcopenia (muscle loss) in people with chronic kidney disease (CKD). Researchers will compare MRI-FF results with standard DXA scans in 868 participants—half with CKD and half without. If proven reliable, MRI-FF could offer a faster, radiation-free way to detect these common complications early.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MRI fat-fraction (MRI-FF) scan
What this could lead to: If successful, this could provide a single, non-invasive scan to detect both osteoporosis and sarcopenia early in CKD patients, improving diagnosis without radiation.
What could go wrong: This is an observational study, not a treatment trial. The MRI-FF method may not prove accurate enough to replace current standards like DXA, and results may not apply to all CKD stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome osteoporosis Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE OSTEOPOROSIS

More trials for these conditions

Other studies related to the condition(s) this trial covers.